The use of a selective, nontoxic dual-acting peptide for breast cancer patients with brain metastasis

Cavaco, Marco; Pérez-Peinado, Clara, 1991-; Valle, Javier; Silva, Rúben D.M.; Gano, Lurdes; Correia, João D.G.; Andreu Martínez, David; Castanho, Miguel A.R.B.; Neves, Vera

The use of a selective, nontoxic dual-acting peptide for breast cancer patients with brain metastasis

Mostra el registre complet Registre parcial de l'ítem

dc.contributor.author Cavaco, Marco
dc.contributor.author Pérez-Peinado, Clara, 1991-
dc.contributor.author Valle, Javier
dc.contributor.author Silva, Rúben D.M.
dc.contributor.author Gano, Lurdes
dc.contributor.author Correia, João D.G.
dc.contributor.author Andreu Martínez, David
dc.contributor.author Castanho, Miguel A.R.B.
dc.contributor.author Neves, Vera
dc.date.accessioned 2024-06-05T06:15:42Z
dc.date.available 2024-06-05T06:15:42Z
dc.date.issued 2024
dc.description.abstract Triple-negative breast cancer (TNBC) is an aggressive subtype characterized by the absence of commonly targeted receptors. Unspecific chemotherapy is currently the main therapeutic option, with poor results. Another major challenge is the frequent appearance of brain metastasis (BM) associated with a significant decrease in patient overall survival. The treatment of BM is even more challenging due to the presence of the blood-brain barrier (BBB). Here, we present a dual-acting peptide (PepH3-vCPP2319) designed to tackle TNBC/BM, in which a TNBC-specific anticancer peptide (ACP) motif (vCPP2319) is joined to a BBB peptide shuttle (BBBpS) motif (PepH3). PepH3-vCPP2319 demonstrated selectivity and efficiency in eliminating TNBC both in monolayers (IC50≈5.0 µM) and in spheroids (IC50≈25.0 µM), with no stringent toxicity toward noncancerous cell lines and red blood cells (RBCs). PepH3-vCPP2319 was also able to cross the BBB in vitro and penetrate the brain in vivo, and was stable in serum with a half-life above 120 min. Tumor cell-peptide interaction is fast, with quick peptide internalization via clathrin-mediated endocytosis without membrane disruption. Upon internalization, the peptide is detected in the nucleus and the cytoplasm, indicating a multi-targeted mechanism of action that ultimately induces irreversible cell damage and apoptosis. In conclusion, we have designed a dual-acting peptide capable of brain penetration and TNBC cell elimination, thus expanding the drug arsenal to fight this BC subtype and its BM.
dc.format.mimetype application/pdf
dc.identifier.citation Cavaco M, Pérez-Peinado C, Valle J, Silva RDM, Gano L, Correia JDG, et al. The use of a selective, nontoxic dual-acting peptide for breast cancer patients with brain metastasis. Biomed Pharmacother. 2024 May;174:116573. DOI: 10.1016/j.biopha.2024.116573
dc.identifier.doi http://dx.doi.org/10.1016/j.biopha.2024.116573
dc.identifier.issn 0753-3322
dc.identifier.uri http://hdl.handle.net/10230/60350
dc.language.iso eng
dc.publisher Elsevier
dc.relation.ispartof Biomed Pharmacother. 2024 May;174:116573
dc.rights.accessRights info:eu-repo/semantics/openAccess
dc.rights.uri http://creativecommons.org/licenses/by-nc/4.0/
dc.subject.keyword Anticancer peptides
dc.subject.keyword BBB peptide shuttle
dc.subject.keyword Blood-brain barrier
dc.subject.keyword Brain metastasis
dc.subject.keyword Cell-penetrating peptides
dc.subject.keyword PepH3
dc.subject.keyword Triple-negative breast cancer
dc.subject.keyword vCPP2319
dc.title The use of a selective, nontoxic dual-acting peptide for breast cancer patients with brain metastasis
dc.type info:eu-repo/semantics/article
dc.type.version info:eu-repo/semantics/publishedVersion

Col·leccions

Articles (Departament de Medicina i Ciències de la Vida)